Train of thought: hand in hand with Corning Jerry to develop PD-L1 new drug

On February 29, thoughtway and Corning Jerry signed a cooperation agreement to develop the first new generation PD-L1 all human monoclonal antibody independently innovated and developed in China According to the agreement, thoughtway will lead the global registration, clinical development and commercialization of new drugs, and Corning Jerry will be responsible for the production of clinical samples in the development stage and the production of post marketing drugs Tumor immunotherapy is the most popular field of tumor research Targeted PD-1 or / and PD-L1 immunotherapy has the potential to treat various types of tumors, and has shown good efficacy in melanoma, lung cancer, renal cancer and bladder cancer Drug development in the immunotherapy field of PD-1 / PD-L1 is extremely hot, and the market peak is expected to reach US $35 billion At present, two PD-1 antibodies have been listed in the world, namely, opdivo of Bristol Myers Squibb and keytruda of MSD However, according to a number of clinical research data, the response rate of these two PD-1 antibodies in different tumor indications is only about 20%, and the incidence of grade 3 / 4 drug-related adverse reactions is high, and drug-related pulmonary toxicity leading to death cases are observed Two monoclonal antibodies against PD-L1, atezolizumab of Roche and durvalumab of AstraZeneca, which are in phase III clinical study, seem to have better safety, and no serious pulmonary toxicity has been observed Therefore, even when two PD-1 antibodies are on the market, FDA still grants them "breakthrough treatment status" According to Dr Xu Ting, CEO of Corning Jerry, the new generation of PD-L1 antibody jointly developed by the company is the result of independent research and development of the company after five years Compared with the current international listed and developing PD-1 and PD-L1 antibodies that need intravenous injection and cryopreservation, it has the advantages of stability at room temperature, subcutaneous injection, etc., so as to greatly reduce the cost of drug production, transportation and use, and improve use Drug compliance It is understood that mindI has carried out the clinical practice of tumor precise treatment since 2012 At present, it has carried out the integrated services of tumor precise diagnosis and treatment (gene detection, prognosis tracking and drug recommendation) in more than 100 large-scale top three hospitals in the country, accumulated and established a high-quality database of tumor gene variation and clinical drug use Relying on the company's professional and efficient information mining and data interpretation capabilities and precision drug development platform, the company has introduced the concept of precision medicine in the pre clinical research and development stage of the new generation of PD-L1 antibody, and will run through the whole clinical development process of new drugs to improve the efficiency of clinical trials and the success rate of new drug development According to Dr Gong Zhaolong, CEO of thoughtway, the company will quickly launch the new generation of PD-L1 antibody global synchronous clinical development, and plans to submit clinical application to CFDA in the second quarter, and submit ind application to FDA It is expected that patients will be enrolled in the third quarter This project will be the first PD-L1 antibody declared by domestic enterprises, and also the first new generation of PD-L1 antibody in clinical development in the world (lislow)